Dermatitis Herpetiformis Refractory to Gluten Free Diet
Launched by TAMPERE UNIVERSITY HOSPITAL · Aug 16, 2023
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Refractory dermatitis herpetiformis refers to dermatitis herpetiformis unresponsive to gluten-free diet therapy. So far, there is very little knowledge on the course of the disease and the causes and prognosis of refractory celiac disease.
Study patients with refractory dermatitis herpetiformis will be recruited. As a control material dermatitis herpetiformis patients with good response to gluten-free dietary treatment will be recruited.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Study patients:
- • Dermatitis herpetiformis diagnosis
- • Dermatitis herpetiformis rash not responding to a strict gluten-free diet after at least 3 years
- Control patients:
- • Dermatitis herpetiformis diagnosis
- • Dermatitis herpetiformis with good response to a gluten-free diet
- Exclusion Criteria:
- Study patients:
- • -Not following strict gluten-free diet
- Control patients:
- • -Not following a strict gluten-free diet
About Tampere University Hospital
Tampere University Hospital (TAYS) is a leading academic medical center in Finland, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, TAYS integrates cutting-edge medical practices with rigorous scientific investigation, focusing on improving patient outcomes and enhancing treatment modalities across various specialties. The hospital collaborates with a network of researchers, healthcare professionals, and academic institutions to foster a multidisciplinary approach to medical research, ensuring that findings are translated into real-world applications for the benefit of patients and the broader healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampere, , Finland
Patients applied
Trial Officials
Kaisa Hervonen, PhD
Principal Investigator
Tampere University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported